Positive outcomes for the use of psilocybin therapy in conjunction with SSRIs have been reported from COMPASS Pathways’ Phase IIb trial.
As the UK sees a record number of drug overdose deaths, calls have been made for the Government to pilot Overdose Prevention Centres in a bid...
BetterLife Pharma has announced its first set of positive data showing the anti-depressant effects of an LSD derivative – 2-bromo-LSD (TD-0148A).
The new UK drug strategy is aiming to reduce drug-related crime through the largest ever increase in funding.
Cybin is to meet with the UK’s Medical and Healthcare Products Regulatory Agency (MHRA) to discuss its lead psychedelic candidate CYB003 as a treatment for Major...
Psyched Wellness presented its proprietary extract of the Amanita Muscaria mushroom, AME-1, to Health Canada representatives to discuss the evidence required in support of a Class...
Ketamine One Capital and Cognetivity Neurosciences have entered into a partnership to study and develop assessments for depression and post-traumatic stress disorder (PTSD).
MYND has received the funding that will go towards its research and development into the effects of psilocybin for treating brain and central nervous system diseases.
The clinical trial is aiming to understand how psilocybin alters brain function in order to improve treatment options for mental illness.
The US Food and Drug Administration (FDA) has given authorisation for a Phase II clinical trial to evaluate psychedelic-assisted psychotherapy for frontline clinicians who are experiencing...
UK-based psychedelics company Albert Labs has received conditional approval for the listing of its common shares on the Canadian Securities Exchange (CSE).
As regulation surrounding psychedelics develops across the globe, Numinus Wellness has created a toxicity and potency screening test that will facilitate safety and efficacy testing of...
